Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-10, Stock:ABBV, The news for the past five days is as follows:
2018-10-03: NEWS1: Top 5 Biotech Stocks for 2018.NEWS2: Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors.NEWS3: Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors.NEWS4: Cramer's lightning round: The sweet spot for buying shares of Clorox.NEWS5: Noteworthy Wednesday Option Activity: FIT, ROST, ABBV.NEWS6: Noteworthy Wednesday Option Activity: FIT, ROST, ABBV.NEWS7: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS8: Here's Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS9: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS10: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS11: Merck & Other Pharma Players Await FDA Decisions in October.NEWS12: Merck & Other Pharma Players Await FDA Decisions in October.NEWS13: Here&apos;s Why J&J (JNJ) is a Good Bet in a Troubled Market.NEWS14: Mylan’s Humira Biosimilar Opportunity in Europe.NEWS15: Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again.NEWS16: The hidden dangers of testosterone replacement therapy you should know about.NEWS17: Nobel Recognizes Science Leading to AbbVie&apos;s Top-Selling Drug.
2018-10-04: NEWS1: Gauging the Impact of AbbVie’s Share Repurchases.NEWS2: What AbbVie’s Valuation Trend Indicates.NEWS3: How Is AbbVie Expected to Fare Going Forward?.NEWS4: IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS5: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018.NEWS6: Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US.NEWS7: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.
2018-10-05: NEWS1: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV.NEWS2: AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis.NEWS3: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS4: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS5: SHAREHOLDER ALERT: PVG OPK USAT TRCO MCHP COCP ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS6: GW Pharmaceuticals: Q3 Performance, Q4 Estimates.NEWS7: AbbVie Inc. Financial Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors.NEWS8: Gilead Announces Positive Data From Ongoing Biktarvy Study.NEWS9: Gilead Announces Positive Data From Ongoing Biktarvy Study.NEWS10: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS11: Analyzing Seattle Genetics’ Key Collaborations.
2018-10-08: NEWS1: 3 Top Biotech Stocks to Buy in October.NEWS2: 3 Top Biotech Stocks to Buy in October.NEWS3: 3 Top Biotech Stocks to Buy in October.NEWS4: SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines.NEWS5: AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS6: AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS7: AbbVie&apos;s Orilissa Gets Canadian Nod to Treat Endometriosis.NEWS8: AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting.
2018-10-09: NEWS1: Pomerantz Law Firm Announces the Filing of a Class Action against AbbVie Inc. and Certain Officers – ABBV.NEWS2: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, MCHP, ABBV, ALNY and CPB.

Answer: Decrease